Abstract
In late 2021, the omicron variant of SARS Coronavirus 2 (SARS-CoV-2) emerged and replaced the previously dominant delta strain. Effectiveness of COVID-19 vaccines against omicron has been challenging to estimate in clinical studies or is not available for all vaccines or populations of interest. T cell function can be predictive of vaccine longevity and effectiveness against disease, likely in a more robust way than antibody neutralization. In this mini review, we summarize the evidence on T cell immunity against omicron including effects of boosters, homologous versus heterologous regimens, hybrid immunity, memory responses and vaccine product. Overall, T cell reactivity in post-vaccine specimens is largely preserved against omicron, indicating that vaccines utilizing the parental antigen continue to be protective against disease caused by the omicron variant.
Keywords: COVID-19; SARS-CoV-2; T cell; omicron; vaccine.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, omicron, T cell, 【초록키워드】 Vaccine, COVID-19 vaccine, Immunity, omicron, Population, Antigen, T cell, COVID-19 vaccines, Effectiveness, Clinical studies, Omicron variant, SARS Coronavirus, SARS coronavirus 2, homologous, disease, Heterologous, Antibody neutralization, Protective, memory response, clinical study, Evidence, Predictive, specimen, regimens, Post-vaccine, Memory responses, dominant, Effect, robust, caused, replaced, reactivity, parental, preserved, 【제목키워드】 Immunity,